BIS:NSD-ProShares UltraShort Nasdaq Biotechnology (USD)

ETF | Trading--Inverse Equity |

Last Closing

USD 17.68

Change

+1.46 (+9.00)%

Market Cap

USD 3.52M

Volume

0.04M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-15 )

Largest Industry Peers for Trading--Inverse Equity

Symbol Name Price(Change) Market Cap
SQQQ ProShares UltraPro Short QQQ

+2.41 (+7.37%)

USD 2.80B
ZBIO Zenas BioPharma, Inc. Common S..

-1.62 (-8.65%)

N/A

ETFs Containing BIS

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Inverse Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.16% 100% F 45% F
Dividend Return 2.61% 50% F 49% F
Total Return 0.45% 100% F 46% F
Trailing 12 Months  
Capital Gain -27.18% 67% D+ 27% F
Dividend Return 2.67% 50% F 39% F
Total Return -24.51% 67% D+ 27% F
Trailing 5 Years  
Capital Gain -72.08% 67% D+ 19% F
Dividend Return 1.67% 100% F 5% F
Total Return -70.41% 67% D+ 19% F
Average Annual (5 Year Horizon)  
Capital Gain 162.39% 67% D+ 94% A
Dividend Return 162.88% 67% D+ 94% A
Total Return 0.49% 67% D+ 15% F
Risk Return Profile  
Volatility (Standard Deviation) 980.71% 67% D+ 5% F
Risk Adjusted Return 16.61% 33% F 49% F
Market Capitalization 3.52M 50% F 5% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.